Journey Medical (DERM) Net Cash Flow (2020 - 2026)

Journey Medical has reported Net Cash Flow for 7 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 309.02% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (down 48.81% YoY), and the FY2025 full-year result was $3.8 million, up 153.06% from the prior year.
• Net Cash Flow for Q1 2026 stood at $3.1 million, up from -$858000.0 in the prior quarter.
• The five-year high for Net Cash Flow was $12.8 million in Q4 2024, with the low at -$9.1 million in Q2 2023.
• Historically, Net Cash Flow has averaged -$403647.1 across 5 years, with a median of -$858000.0 in 2025.
• The largest YoY upside for Net Cash Flow was 420.81% in 2025 against a maximum downside of 435.86% in 2025.
• Journey Medical's Net Cash Flow stood at -$2.9 million in 2022, then jumped by 193.14% to $2.7 million in 2023, then soared by 377.47% to $12.8 million in 2024, then tumbled by 106.68% to -$858000.0 in 2025, then jumped by 464.69% to $3.1 million in 2026.
• The last three Net Cash Flow figures came in at $3.1 million (Q1 2026), -$858000.0 (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.